Integra LifeSciences (NASDAQ:IART) Releases FY 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 2.400-2.500 for the period, compared to the consensus earnings per share estimate of 2.450. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its Q3 2026 guidance to 0.530-0.610 EPS.

Integra LifeSciences Stock Up 3.7%

IART opened at $17.10 on Friday. The firm’s 50 day simple moving average is $17.67 and its two-hundred day simple moving average is $13.45. The company has a market capitalization of $1.33 billion, a PE ratio of -189.95, a PEG ratio of 1.14 and a beta of 1.22. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.49. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. The firm had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.31%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, equities analysts forecast that Integra LifeSciences will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

IART has been the topic of several recent research reports. Wells Fargo & Company raised their price objective on Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Thursday. Citigroup reiterated a “neutral” rating and set a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. Truist Financial raised their target price on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. BMO Capital Markets initiated coverage on shares of Integra LifeSciences in a report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price target on the stock. Finally, Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $18.86.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds have recently modified their holdings of the stock. Rubric Capital Management LP boosted its position in shares of Integra LifeSciences by 1.3% during the fourth quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock worth $96,304,000 after acquiring an additional 100,000 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Integra LifeSciences by 0.9% during the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after purchasing an additional 31,931 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Integra LifeSciences by 9.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after purchasing an additional 267,134 shares during the last quarter. State Street Corp grew its position in shares of Integra LifeSciences by 0.8% during the fourth quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock valued at $34,933,000 after purchasing an additional 21,717 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY increased its holdings in shares of Integra LifeSciences by 5.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 2,664,998 shares of the life sciences company’s stock worth $33,099,000 after purchasing an additional 135,198 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.